Anya Biopharm Inc.

Anya Biopharm Inc. is a biotechnology and pharmaceutical company headquartered in Taipei, Taiwan. The company specializes in the development of oral peptide drug delivery platforms, addressing challenges such as low bioavailability and limited formulation options that traditionally hinder oral administration of peptide-based therapeutics. Its proprietary Mira/Je® technology is designed to enhance the stability and absorption of a wide range of peptides and has been successfully applied in both clinical and preclinical studies for various compounds, including therapies for diabetes and obesity. The company’s lead investigational drug, a GLP-1 receptor agonist formulated for oral delivery, targets type 2 diabetes and obesity management, reflecting the firm's focus on metabolic and chronic disease markets. Anya Biopharm’s approach leverages scalable, safe manufacturing processes and a flexible platform adaptable to collaboration with other pharmaceutical developers. As a prominent innovator in this niche, Anya Biopharm plays a significant role in advancing the oral peptide therapeutics sector within the broader biotechnology and medical research industry.